Credits Earned (2024) Crédits obtenus

Redeem Prepaid Membership

Tools for Practice Outils pour la pratique


#104 Aldosterone antagonists in Heart Failure with Reduced Ejection Fraction (HFrEF) – No longer an afterthought.


CLINICAL QUESTION
QUESTION CLINIQUE
What is the role of aldosterone antagonists in patients with chronic HFrEF?


BOTTOM LINE
RÉSULTAT FINAL
Aldosterone antagonists reduce mortality and hospitalizations in patients with HFrEF (Class II–IV). The benefit appears similar to β-blockers or ACE inhibitors. Close monitoring is required for those at risk of hyperkalemia.  



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Two randomized controlled trials: 
  • RALES:1 1,663 patients with NYHA class 3-4 heart failure with HFrEF on ACE inhibitors and diuretics. Given spironolactone or placebo. At 24 months: 
    • Statistically significant reduction in: 
      • Mortality: Spironolactone 35%, placebo 46%, Number Needed to Treat (NNT)=10. 
      • Cardiovascular hospitalization: 32% vs. 40%, NNT=12. 
    • Adverse events: 
      • Gynecomastia/breast pain in men: Spironolactone 10%, placebo 1%, Number Needed to Harm (NNH)=11. 
      • Serious hyperkalemia (potassium ≥6 mmol/L): Not statistically different. 
  • EMPHASIS-HF:2 2,737 patients with NYHA class II HFrEF with majority on ACE inhibitors, and β-blockers. Given eplerenone or placebo. At 21 months: 
    • Statistically significant reduction in: 
      • Mortality: eplerenone 13%, placebo 16%, NNT=34. 
      • Cardiovascular hospitalization: 22% vs. 29%, NNT=15. 
    • Adverse events: 
      • Hyperkalemia (>5.5 mmol/L) increased with eplerenone 12%, placebo 7%, NNH=22. 
      • No difference in gynecomastia or renal failure. 
Two meta-analyses found similar results.3,4 

CONTEXT
CONTEXTE
  • Aldosterone antagonists compare favourably to other agents used in HFrEF whose relative risk reductions for mortality are: 
    • Aldosterone antagonists1,2 ~25%. 
    • β-blockers5 ~29%. 
    • ACE inhibitors6,7 ~23%. 
  • Aldosterone antagonists are prescribed at less than half the rate of β-blockers and ACE inhibitors, and represent the greatest potential for increased HFrEF survival.8 
  • Titration to target doses of ACE inhibitors and β-blockers before adding aldosterone antagonists has been advocated,9 however the usage/doses of these medications were quite different in RALES and EMPHASIS-HF, yet they had similar outcomes. 
  • There is no head-to-head trial of spironolactone vs. eplerenone. Spironolactone ($12/month) could be used first and, if gynecomastia/breast pain develop, switch to eplereonone ($100/month). 


Latest Tools for Practice
Derniers outils pour la pratique

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Read Lire 0.25 credits available Crédits disponibles

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Read Lire 0.25 credits available Crédits disponibles

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Adrienne J Lindblad BSP ACPR PharmD
  • G. Michael Allan MD CCFP
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. Pitt B, Zannad F, Remme WJ, et al. N Engl J Med. 1999; 341(10):709–17.

2. Zannad F, McMurray JJ, Krum H, et al. N Engl J Med. 2011; 364(1):11–21.

3. Ezekowitz JA, McAlister FA. Eur Heart J. 2009 Feb; 30(4):469–77.

4. Hu LJ, Chen YQ, Deng SB, et al. Br J Clin Pharmacol. 2013; 75(5):1202–12.

5. Bonet S, Agusti A, Arnau JM, et al. Arch Intern Med. 2000; 160:621–7.

6. Garg R, Yusuf S. JAMA. 1995 May 10; 273(18):1450–6.

7. Flather MD, Yusuf S, Kober L, et al. Lancet. 2000; 355:1575–81.

8. Fonarow GC, Yancy CW, Hernandez AF, et al. Am Heart J. 2011 Jun; 161(6):1024–30.

9. McKelvie RS, Moe GW, Ezekowitz JA, et al. Can J Cardiol. 2013; 29(2):168–81.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 26/03/2018

By: RIcky D Turgeon BSc(Pharm) ACPR PharmD, G Michael Allan MD CCFP

Comments:

Reviewed: March 26, 2018. Evidence update: None. Bottom line: unchanged.

Learning at a glance
Yearly credits
Acquired ()
Your content by topic
Cardiology Dermatology Emergency
My Bookmarks